Date: 2013-08-06
Type of information: Collaboration agreement
Compound: biosimilar versions of Humira®, Rituxan®, Avastin®, and Herceptin®
Company: Oncobiologics (USA - NY) inVentiv Health (USA - NJ)
Therapeutic area: Cancer - Oncology - Autoimmune diseases
Type agreement: collaboration development
Action mechanism: biosimilar/monoclonal antibody
Disease:
Details: * On August 6, 2013, Oncobiologics and inVentiv Health announced a broad strategic partnership around clinical development for all assets in Oncobiologic’s pipeline. The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules. Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials. As the assets are commercialized, the partnership will be broadened to include inVentiv’s significant commercialization capabilities in select countries. This will position Oncobiologics attractively in seeking future commercial partners. The current biosimilar assets include generic versions of Humira®, Rituxan®, Avastin®, Herceptin® and Erbitux®.
Financial terms:
Latest news:
